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For over a century, inactivated or attenuated bacteria have been employed in the clinic as
immunotherapies to treat cancer, starting with the Coley’s vaccines in the 19th century
and leading to the currently approved bacillus Calmette-Guérin vaccine for bladder cancer.
While effective, the inflammation induced by these therapies is transient and not designed
to induce long-lasting tumor-specific cytolytic T lymphocyte (CTL) responses that have
proven so adept at eradicating tumors. Therefore, in order to maintain the benefits
of bacteria-induced acute inflammation but gain long-lasting anti-tumor immunity, many
groups have constructed recombinant bacteria expressing tumor-associated antigens
(TAAs) for the purpose of activating tumor-specific CTLs. One bacterium has proven
particularly adept at inducing powerful anti-tumor immunity, Listeria monocytogenes (Lm).
Lm is a gram-positive bacterium that selectively infects antigen-presenting cells wherein
it is able to efficiently deliver tumor antigens to both the MHC Class I and II antigen
presentation pathways for activation of tumor-targeting CTL-mediated immunity. Lm is
a versatile bacterial vector as evidenced by its ability to induce therapeutic immunity
against a wide-array of TAAs and specifically infect and kill tumor cells directly. It
is for these reasons, among others, that Lm-based immunotherapies have delivered
impressive therapeutic efficacy in preclinical models of cancer for two decades and are
now showing promise clinically. In this review, we will provide an overview of the history
leading up to the development of current Lm-based immunotherapies, the advantages
and mechanisms of Lm as a therapeutic vaccine vector, the preclinical experience with
Lm-based immunotherapies targeting a number of malignancies, and the recent findings
from clinical trials along with concluding remarks on the future of Lm-based tumor
immunotherapies.
Keywords: Listeria monocytogenes, tumor immunotherapy, cancer vaccines, tumor-associated antigens, vaccine
vectors and adjuvants
INTRODUCTION
Tumor immunotherapy is currently gaining momentum as an
invaluable therapeutic strategy for cancers refractory to tradi-
tional treatments or those with no effective therapeutic options.
The recent FDA-approval of the first antigen-specific tumor
immunotherapy, Sipleucel-T for prostate cancer (also known as
Provenge), and the introduction of an immune checkpoint mod-
ulating therapeutic, Ipilumimab for metastatic melanoma, are
part of a new wave of immunotherapies that bring with them
the promise of improved efficacy and reduced adverse events
in comparison to chemotherapy and radiation (Hodi et al.,
2010; Kantoff et al., 2010a). In this review, we will provide
a detailed overview of another promising immunotherapeutic
approach still in development, Listeria monocytogenes (Lm)-based
vaccines. This review will cover the important developments
leading up to the application of Lm in tumor immunotherapy
(depicted in Figure 1), the mechanisms governing efficacy by
Lm-based tumor vaccines, the preclinical and clinical experience
with Lm-based tumor vaccines, and concluding remarks on their
future.
ATTENUATED OR INACTIVATED BACTERIA AS NON-SPECIFIC TUMOR
IMMUNOTHERAPY
Modern tumor immunotherapy has its beginnings in the late-
20th century with the introduction of IL-2 for advanced kidney
cancer but the field is influenced by a history of immunization
with attenuated or inactivated pathogens that dates back mil-
lennia (Rosenberg et al., 1987). From ninth century Asia, where
physicians administered an attenuated variola virus to prevent
smallpox to the eighteenth century development of the first vac-
cine for smallpox by Fenner (1993), we have become increasingly
successful at employing attenuated and inactivated pathogens that
safely and effectively mobilize immunity against infectious dis-
eases. However, the application of a similar approach to mobilize
therapeutic immunity against cancer has been complicated by
obstacles that still hinder most active tumor immunotherapies.
One of the most apparent difficulties of applying a similar strat-
egy is that tumors are self-tissue for which our immune system
is tolerant (Hogquist et al., 2005). However, even with this tol-
erance, anti-tumor immune responses are observed in patients
but they are poorly functional and insufficient to eliminate
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FIGURE 1 | Pivotal events in the development of Lm-based vaccines for
tumor immunotherapy. The last two decades have seen the emergence of
Lm-based vaccines and their first clinical application for cancer. In this
timeline (not to scale), we depict several pivotal events that have led to their
current stage of development and point to a future with improved Lm-based
vaccines and treatment strategies.
the malignancy (Ahmadzadeh et al., 2009). An early indication
for a strategy to overcome this tolerance and enhance anti-
tumor immunity came from observations by Vautier in 1813
detailing tumor regression in patients infected with Clostridium
perfingens (Hall, 1998). In 1851, a Belgian doctor named Didot
reported on the successful treatment of terminal cancer patients
by deliberately giving them syphilis (Hall, 1998). However, obser-
vational evidence and a small study performed by a German
scientist Busch suggested that infection with Streptococcus pyo-
genes was the most effective method to induce tumor regres-
sions (Hall, 1998). Building on observations from Vautier and
others regarding the clinical benefit of bacterial infection in
cancer patients, the first systematic studies were performed by
William Coley with heat-inactivated mixtures of bacteria known
as Coley’s toxins (Coley, 1991). William Coley, a bone surgeon
at Memorial Sloan-Kettering in the late nineteenth and early
twentieth century, treated his cancer patients with an inacti-
vated bacterial mixture that consisted mainly of Streptococcus
pyogenes and Serratia marcescens in order to activate non-specific
anti-tumor immunity. Inoculation with the Coley’s toxin or
“Coley’s vaccine” resulted in a significant number of partial
and complete responses in these patients. The advent of radi-
ation therapy brought about the demise of this approach but
interest in similar approaches has been gaining acceptance in
recent decades (Wiemann and Starnes, 1994; Karbach et al.,
2012). In fact, attenuated Mycobacterium bovis, specifically the
Bacillus Calmette-Guerin (BCG) strain, is currently in use as an
immunotherapy for bladder cancer (Herr et al., 1995). Much
like Coley’s toxins, BCG is utilized as a non-specific immune
stimulant.
CURRENT STRATEGIES FOR ACTIVATING TUMOR-SPECIFIC IMMUNITY
Non-specific activation of innate immunity has found some
clinical success but the current field is now focused on the devel-
opment of more effective and specific immunotherapies that acti-
vate cytotoxic T lymphocytes (CTL) targeting tumor-associated
antigens (TAAs). In fact, the first FDA-approved active tumor
immunotherapy, Sipleucel-T, was developed using this CTL-
mediated strategy (Kantoff et al., 2010a). To activate TAA-specific
CTLs, Sipleucel-T is comprised of a patient’s PBMCs that are
treated with granulocyte macrophage colony-stimulating factor
(GM-CSF) fused to the prostate cancer specific antigen, prostatic
acid phosphatase (PAP). The activated, PAP epitope-presenting
PBMCs are then administered back to the patient in order to
induce CD8+ T cells that recognize and lyse prostate tumor cells
expressing PAP. The end result of this therapy is increased patient
survival of roughly 4 months in those with advanced disease.
While the extended lifespan afforded by Sipleucel-T is certainly
encouraging, the relatively high cost and labor required to make
a treatment specific to each patient makes this option less than
ideal for widespread application. Fortunately, there are a num-
ber of therapeutic vaccines utilizing attenuated viral and bacterial
pathogens as vectors in clinical and preclinical testing that mit-
igate many of these issues while promising potentially greater
efficacy (Paterson et al., 2010; Larocca and Schlom, 2011). These
promising attenuated pathogen vectors do come with their own
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set of advantages and disadvantages as well. Viral vectors such as
the commonly used modified vaccinia virus Ankara (MVA) strain
have the advantage of delivering genes encoding large antigens
that bacterial vectors have difficulty properly secreting (Jacobs
et al., 2009; Wood et al., 2011). The major disadvantage of MVA-
based and other viral vaccine vectors, however, is that they are
no longer able to boost immunity after the second immuniza-
tion due to induction of neutralizing antibodies (Kundig et al.,
1993). To overcome this drawback, recent studies have found
some success by boosting with recombinant fowlpox virus vec-
tors that do not develop neutralizing antibodies but induce less
robust immune responses (Taylor and Paoletti, 1988; Kantoff
et al., 2010b). In contrast, there is either a minor or equivo-
cal impact of preexisting immunity on the efficacy of the two
most common bacteria-based vectors for tumor immunotherapy,
Salmonella typhimurium (Salmonella) and Listeria monocytogenes
(Lm) (Tvinnereim et al., 2002; Sevil Domenech et al., 2007, 2008;
Leong et al., 2009; Saxena et al., 2009). In addition, the mini-
mal negative impact of preexisting immunity on responses to a
delivered antigen by Lm can be mitigated with repeated boosting
(Leong et al., 2009). The difference between these bacterial vectors
becomes readily apparent, however, when comparing their life
cycle and subcellular localization. In lymphoid organs, Salmonella
is taken up into the phagosome of infected macrophages where it
remains sequestered and slowly replicates (Haraga et al., 2008).
Lm is also taken up into phagosomes but is able to escape into the
cytosol where it rapidly divides and delivers antigens efficiently to
the MHC I presentation pathway (Portnoy et al., 2002). This effi-
cient delivery of antigens to the cytosol by Lm results in a more
rapid antigen-specific cellular response and greater anti-tumor
efficacy in comparison to a Salmonella vector expressing the same
antigen (Stark et al., 2009). Interestingly, Nishikawa et al. discov-
ered a method to improve Salmonella delivery of antigens to the
cytosol and induce tumor-specific CTL responses through the use
of the Type III secretion system (Nishikawa et al., 2006). While
the number of studies is limited, Lm-based vaccines for cancer
have also demonstrated greater therapeutic benefit in clinical tri-
als as compared to a Salmonella-based vaccine (Toso et al., 2002;
Maciag et al., 2009; Le et al., 2012; Petit and Basu, 2013). Due
to these advantages and others outlined below, Lm is one of our
most promising vectors available for tumor immunotherapy and
the focus of this review.
ATTENUATED Lm AS A POWERFUL VECTOR FOR TARGETED TUMOR
IMMUNOTHERAPY
Lm infection and host response
Listeria monocytogenes is a gram-positive bacterium that is com-
monly associated with gastrointestinal infections through the
consumption of contaminated food. As a gastrointestinal infec-
tion, Lm infects epithelial cells in the small intestine through
the function of a virulence factor known as Internalin A (InlA)
(Gaillard et al., 1991). InlA specifically interacts with E-cadherin
expressed on the basolateral surface of polarized epithelium to
facilitate invasion into a cell (Pentecost et al., 2006). After invad-
ing the gut epithelium, Lm then migrates to other organs such
as the spleen where it is phagocytized by antigen-presenting cells
(APCs). Inside the cell, a prfA-mediated virulence gene program
in Lm facilitates its survival and propagation (Freitag et al., 1993).
PrfA is a Lm-specific transcriptional activator of many virulence
factors such as the pore-forming toxin Listeriolysin O (LLO) and
phospholipases that coordinate to compromise the integrity of
phagosomal membranes and allow for Lm escape into the cytosol
of the infected cell (Mengaud et al., 1987). Once it has escaped
from the phagosome, Lm propels through the cytosol through the
action of ActA, a protein that interacts with the Arp2/3 complex
to activate the nucleation of actin filaments. It is this cytosolic
motility of Lm that allows it to impact the cellular membrane with
enough force to form a protrusion that is recognized and inter-
nalized by a proximal cell, therefore, disseminating the infection
(Tilney and Portnoy, 1989).
The host response to infection by Lm is evident in both the
strong innate response to the intracellular pathogen during an
acute infection and the generation of strong adaptive responses to
counter future challenges with Lm. The innate response to Lm is
initially mediated by surface toll-like receptors (TLRs) that recog-
nize bacterial pathogen-associated molecular patterns (PAMPs)
from Lm such as lipoteichoic acid (Machata et al., 2008; Noor
et al., 2008). Activation of TLRs by Lm results in downstream
signaling through the MyD88 adaptor protein and production of
proinflammatory cytokines (Edelson and Unanue, 2002). Once
phagocytized, Lm may then be processed in the phagolysosomal
compartment and peptides presented onMHCClass II for activa-
tion of Lm-specific CD4+ T cell responses. Alternatively, Lm can
escape the phagosome and enter the cytosol where recognition
of peptidoglycan by nuclear oligomerization domain-like recep-
tors (NLRs) and Lm DNA by the DNA sensor, AIM2, activates
inflammatory cascades (Kobayashi et al., 2005; Hasegawa et al.,
2006; Park et al., 2007; Sauer et al., 2010; Warren et al., 2010).
Once in the cytosol, Lm also secretes protein antigens that are
processed and presented by MHC Class I molecules to CD8+ T
cells for robust induction of Lm-specific CTL responses that pro-
vide protection against a subsequent exposure (Brunt et al., 1990).
This combination of inflammatory responses and efficient deliv-
ery of antigens to the MHC I and MHC II pathways makes Lm a
powerful vaccine vector.
Lm as a vaccine vector for delivery of foreign antigens
The ability of Lm to induce strong cellular immune responses
has led to its use for decades as a tool to dissect the mecha-
nisms of immune memory formation and function (North, 1973;
Stolpmann et al., 1985; Shedlock et al., 2003; Shen et al., 2003).
However, it was not until several studies in the early 1990s that the
enormous translational potential of Lm as an inducer of antigen-
specific CTLs was realized (Schafer et al., 1992; Ikonomidis et al.,
1994; Frankel et al., 1995; Pan et al., 1995a,b). In the initial study,
Paterson and colleagues constructed recombinant strains of Lm
that expressed a foreign antigen, E. coli β-galactosidase (β-gal)
(Schafer et al., 1992). When mice were immunized either par-
enterally or orally with these constructs, β-gal-specific CTLs were
induced and delayed type-hypersensitivity reactions to β-gal were
observed in mice receiving the recombinant Lm strain but not
a wild-type Lm strain. Building on this success, Paterson and
colleagues further developed and refined the Lm vaccine plat-
form with a construct that expressed a viral antigen, influenza
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nucleoprotein (NP) (Ikonomidis et al., 1994). However, this Lm
vaccine sought to improve the processing and presentation of
the foreign antigen by use of a strategy still used in Lm-based
vaccines to this day. Unlike the β-gal Lm construct, the Lm-NP
construct expressed the antigen as a fusion protein with the first
420 amino acids of Listeriolysin O. This LLO-NP fusion protein
lacked the cholesterol-binding domain at the C-terminus of LLO
necessary for pore formation and was, therefore, detoxified while
still containing the signal sequence at the N-terminus allowing
for efficient secretion (Michel et al., 1990). The rationale behind
this approach was that the improved secretion of the foreign anti-
gen into the cytosol of infected cells would increase the efficiency
of processing and presentation to match the immunogenicity of
endogenous Lm antigens. In fact, Lm-NP infected cells were able
to efficiently process and present NP peptides for recognition
by NP-specific CTLs. Consequently, Lm-NP constructs induced
a highly functional CTL response against NP that was depen-
dent on the ability of the constructs to deliver antigen to the
cytosol, as LLO-deficient constructs were ineffective. The major
advancement from this work of improving the processing and
presentation of foreign antigens by Lm-based vaccines allowed
for future application of this technology in CTL-mediated tumor
immunotherapy.
Initial application of Lm vaccines in tumor immunotherapy
After confirming the potential of Lm-based vectors to induce
robust CTL responses against foreign antigens, Paterson and
colleagues applied this technology to the then nascent field of
tumor immunotherapy (Pan et al., 1995a). Much like infected
cells, tumor cells can be recognized and lysed by antigen-specific
CTLs (Freedman et al., 1972). Therefore, to assess the poten-
tial for Lm-based vaccines to induce effective anti-tumor CTL
responses, the team utilized the previously constructed Lm-
NP vaccine strain along with tumor cell lines that expressed
NP as a model tumor antigen (Pan et al., 1995a). When mice
were vaccinated with the Lm-NP vaccine, it provided prophy-
lactic protection against tumor formation after challenge. In
addition, after first allowing for tumors to form and estab-
lish, therapeutic intervention was effective at reducing tumor
volume. This regression by Lm-NP correlated with infiltration
of T cells into the tumor after vaccination and was abrogated
after antibody-mediated depletion of T cells. A subsequent study
by Jensen and colleagues also found Lm-based vaccines to be
effective as a prophylactic against cottontail rabbit papilloma
virus (CRPV) induced papillomas, a model for virus-induced
malignant transformation (Brandsma, 1994). After previous suc-
cess generating virus-specific CTL responses with recombinant
Lm, they developed a novel Lm strain expressing the CRPV
E1 antigen, E1-rLm, that induced cellular immune responses
against E1 and protected the rabbits from papilloma forma-
tion (Shen et al., 1995; Slifka et al., 1996; Jensen et al., 1997).
Therefore, the summation of these studies validated Lm as a
viable platform for the delivery of TAAs in both a prophylactic
and therapeutic setting. The promise demonstrated by these ini-
tial vaccines resulted in the development of numerous Lm-based
immunotherapies, many outlined in this review, that continues to
this day.
MECHANISMS OF Lm-BASED VACCINE VECTORS FOR
TUMOR IMMUNOTHERAPY
Early studies demonstrated the powerful potential of Lm-based
immunotherapies for cancer but the mechanisms governing their
efficacy are still under investigation. We describe, in detail below
and depicted in Figure 2, important advances in our understand-
ing of Lm-based immunotherapy efficacy that continue to guide
its development.
ENHANCED PROCESSING AND PRESENTATION OF Lm-DELIVERED
ANTIGENS
The initial rationale for the use of Lm as a vaccine vector was to
harness its ability to deliver antigens efficiently to both the MHC
Class I and II presentation machinery and induce robust T-cell
responses to Lm-derived antigens (Naher et al., 1985; Lukacs and
Kurlander, 1989; Brunt et al., 1990; Schafer et al., 1992; Hsieh
et al., 1993). However, recent studies suggest that the robust
CD8+ T cell responses to Lm-derived antigens are not simply
due to proficient cytosolic delivery. In fact, Lm-derived antigens
appear to be processed and presented on MHC Class I by a ded-
icated, high-efficiency pathway (Wolf and Princiotta, 2013). In a
study by Wolf and Princiotta, Lm-based vectors were constructed
that expressed influenza NP fused to the first 100 amino acids
of ActA in order to allow for proper secretion of the antigen
(Wolf and Princiotta, 2013). However, one construct expressed
the fusion protein with an arginine at the N-terminus of NP
to give the protein a half-life of 10min while the unmodified
fusion protein had a half-life of several days. Interestingly, APCs
infected with either Lm-based construct presented an epitope
peptide from the antigen on MHC Class I with the same effi-
ciency. This result suggests that Lm-derived antigens are presented
with high-efficiency independent of the protein half-life. This
high-efficiency presentation pathway was exclusive for Lm as a
viral vector delivering the same antigens resulted in presentation
that directly correlated with protein half-life. Therefore, this evi-
dence provides additional rationale for the use of Lm as a CTL
vaccine vector and elucidates an additional mechanism for the
robust T cell responses induced by Lm-based immunotherapies.
ACTIVATION OF INNATE IMMUNITY BY Lm-DERIVED PAMPs
Detoxified listeriolysin O (dtLLO)
Listeriolysin O is a cholesterol-dependent cytolysin that, upon
secretion by Lm, binds to cholesterol-containing membranes and
forms a barrel resulting in a membrane pore (Shatursky et al.,
1999). LLO-mediated pore formation results in reduced phago-
some membrane integrity and aids the escape of Lm from the
phagosomes of APCs (Geoffroy et al., 1987; Tilney and Portnoy,
1989; Beauregard et al., 1997). While the acidic environment
of the phagosome increases the lytic activity of LLO for this
purpose (Glomski et al., 2002), others have also found extracel-
lular secretion of LLO by Lm that directly lyses T cells (Carrero
et al., 2004). In a therapeutic setting, LLO has proven a power-
ful adjuvant but only after this lytic activity is reduced though
“detoxification” with mutation or truncation of its cholesterol-
binding domain (Michel et al., 1990). The first use of a detoxified
LLO (dtLLO) in a tumor immunotherapy setting was in the
context of a genetic fusion with a tumor-specific antigen (Pan
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FIGURE 2 | Mechanisms of Lm-based vectors in tumor immunotherapy.
Several mechanisms governing the efficacy of Lm-based immunotherapies
are depicted in the accompanying figure. (1) There are several very effective
methods of attenuation available to construct a highly immunogenic
Lm-based vector usually involving deletion of one or more virulence genes.
(2) Once attenuated, Lm-based vectors are highly versatile producers of
tumor-associated antigens and other therapeutic proteins. (3) After
administration, Lm-based vaccines selectively infect antigen-presenting cells,
escape the phagosome, and secrete tumor-associated antigens that are
delivered to a high-efficiency processing and presentation pathway for
activation of tumor-specific CTLs. (4) The detection of Lm-derived PAMPs
facilitates tumor-specific CTL activation through the upregulation of
costimulatory molecules and the secretion of proinflammatory cytokines. (5)
The resultant effect of Lm-based vaccination is the ability to break central
tolerance and produce therapeutic anti-tumor CTL responses against self
TAAs. (6) This tumor-specific CTL response is further aided by reduced
tumor-associated immunosuppression as evidenced by diminished
functionality and lower numbers of Tregs and MDSCs in the tumor
microenvironment after Lm-based vaccination. (7) In addition to activation of
tumor-specific CTL responses, recent reports demonstrate the ability of
Lm-based vaccines to target primary and metastatic tumors for infection and
directly kill tumor cells. Each of these mechanisms of Lm-based vaccines
highlight their powerful potential as vectors for tumor immunotherapy and
their versatility in terms of construction and efficacy.
et al., 1995a). Fusion of the antigen to dtLLO and secretion
by Lm was found to significantly enhance anti-tumor immune
responses in comparison to an Lm vector that secreted only the
tumor antigen (Gunn et al., 2001). The likely mechanisms for
this adjuvancy effect of dtLLO are several. The N-terminus of
dtLLO contains an N-degron, a destabilizing residue that medi-
ates processing by the Ub-proteasome machinery (Schnupf et al.,
2006, 2007). Therefore, it was hypothesized that tumor antigens
genetically fused to the C-terminus of dtLLO may have enhanced
Ub-proteasome-mediated processing and presentation by APCs
for activation of antigen-specific CTLs. More recently, several
studies have inspected the potential for dtLLO to function as a
PAMP and stimulate the necessary proinflammatory responses
for effective anti-tumor adaptive immune responses (Peng et al.,
2004, 2007; Wallecha et al., 2013b). A study by Wallecha et
al found that purified dtLLO administered as a fusion protein
with human papilloma virus type 16 E7 protein (HPV16 E7),
a TAA expressed by HPV-transformed malignancies, or unfused
in a mixture with HPV16 E7 can augment anti-E7 CD8+ T cell
responses and therapeutically impact growth of murine tumors
that express E7 (Wallecha et al., 2013b). To determine if the
mechanism of adjuvancy was through PAMP-like activity, bone
marrow-derived dendritic cells (BMDC) from wild-type mice
were stimulated in vitro with dtLLO. dtLLO stimulation resulted
in induction of proinflammatory cytokines such as IL-12 and
increased expression of markers associated with BMDC matu-
ration. While previous studies have suggested that PAMP-like
activity of LLO and other cytolysins is dependent on TLR4 (Park
et al., 2004), dtLLO treatment resulted in TLR4-independent
induction of transcript for proinflammatory cytokines and cos-
timulatory molecules suggesting additional mechanisms for this
activity. These results suggest that the fusion or conjugation of
dtLLO to antigen is likely not required to improve immunogenic-
ity as previous studies with DNA vaccines suggested but this is yet
to be determined in an Lm-based vaccine approach (Peng et al.,
2007).
ActA
ActA production by Lm is essential to its cytoplasmic motility and
cell-to-cell spread due to its ability to nucleate actin through the
Arp2/3 complex (Welch et al., 1998). However, much like dtLLO,
it is a powerful adjuvant as its fusion to Lm-secreted antigens
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results in enhanced immunogenicity (Sewell et al., 2004a, 2008;
Souders et al., 2007). In work published by Sewell et al, secre-
tion of HPV16 E7 fused to ActA resulted in significantly enhanced
immunogenicity of E7 resulting in effective anti-tumor immune
responses (Sewell et al., 2004a). The use of ActA as an adjuvant
is not only restricted to Lm-based vaccines, as it also enhances
antigen-specific anti-tumor immune responses in DNA and pro-
tein vaccine formulations (Wood et al., 2010). The promising
potential of ActA in Lm-based vaccines was demonstrated by its
ability to activate highly effective anti-tumor immune responses
even to tolerized antigens (Souders et al., 2007; Sewell et al.,
2008). Fusion of ActA to an antigen may increase immunogenic-
ity through increased antigen processing and presentation due to
the presence of several putative PEST domains in the N-terminus
of ActA. However, ActA is a relatively stable protein (Moors et al.,
1999). In support of an alternative mechanism, a subsequent
study suggests the adjuvant properties of ActA are independent
of fusion to the antigen (Sewell et al., 2004b; Wood et al., 2010).
In fact, ActA protein appears to have PAMP-like properties due to
its ability to induce proinflammatory cytokines and maturation
of BMDCs (Wood et al., 2010).
Cyclic di-AMP
The discovery of cyclic di-AMP as the Type I interferon (IFN)-
inducing molecule by Lm was critical to our understanding of the
host response to Lm (Woodward et al., 2010; Schwartz et al., 2012;
Witte et al., 2013). Cyclic di-AMP is a small dinucleotide secreted
by Lm once it escapes the phagosome of an infected cell and enters
the cytosol. Within the cytosol, Lm-derived cyclic di-AMP acti-
vates a mitochondrial transmembrane receptor, STING, leading
to Type I IFN production (Ishikawa and Barber, 2008). Type I
IFN induced by Lm and other intracellular facultative bacteria
can increase their acute pathogenicity and recent evidence sug-
gests it may even hinder formation of adaptive immunity to Lm
(Auerbuch et al., 2004; O’connell et al., 2004; Archer et al., 2014).
However, there is a growing body of evidence emphasizing the
importance of Type I IFN signaling in tumor immunosurveillance
and the formation of effective anti-tumor adaptive immunity
(Diamond et al., 2011; Fuertes et al., 2011). Therefore, methods
that modulate cyclic di-AMP in Lm-based tumor immunother-
apy may be promising but will require a delicate balance between
its ability to impair or enhance anti-tumor immunity.
OVERCOMING CENTRAL TOLERANCE TO TAAs
The preclinical success of Lm-NP in mouse tumor models pre-
saged the current promising results of Lm-based vaccines target-
ing tumor-associated viral antigens in clinical trials (Maciag et al.,
2009; Petit and Basu, 2013). It is likely that some of this success is
due to the targeting of a viral antigen for which there is no cen-
tral tolerance to limit CTL responses. However, effective targeting
of self-TAAs is currently a necessity in tumor immunotherapy
as the number of virus-associated malignancies containing viral
TAAs is unknown. Therefore, in order to determine if Lm-based
immunotherapies can effectively overcome central tolerance to
self-TAAs, an E6/E7 transgenic mouse was developed with expres-
sion of HPV16 E6 and E7 oncogenes under the control of the thy-
roglobulin promoter to drive expression in the thyroid and also
in medullary thymic epithelial cells (Souders et al., 2007). HPV16
E6 and E7 expression in the thyroid results in hyperplasia start-
ing at 2 months of age with malignant transformation evident
by the formation of papillary carcinomas starting at 6 months
of age. Initial work in this E7-tolerized mouse model found
that Lm-LLO-E7 vaccination was able to break central tolerance
and induce regression of implanted TC.1 tumors. TC.1 tumors
stably express HPV16 E6 and E7 along with H-ras and are a
common model for preclinical immunotherapies targeting HPV-
induced cancer (Lin et al., 1996). Further studies determined that
Lm-LLO-E7, along with an additional Lm-based immunother-
apy secreting E7 fused to ActA, Lm-ActA-E7, were also effective
at reducing the development of autochthonous thyroid tumors
(Sewell et al., 2008). However, elimination of TC.1 tumors by
Lm-LLO-E7 was less effective than in wild-type mice. The rea-
son for this reduced efficacy appeared to not be due to increased
numbers of T regulatory cells (Tregs) but the generation of lower
avidity CTLs in the E6/E7 transgenic mouse as compared to the
wild-type mouse after Lm-LLO-E7 vaccination. Nevertheless, the
demonstration of anti-tumor efficacy in a tolerized animal model
provided the rationale for future Lm-based immunotherapies to
target self-TAAs such as Her2/neu and VEGFR-2 (Singh et al.,
2005; Singh and Paterson, 2006a,b, 2007a,b; Seavey et al., 2009b).
REDUCTION OF TUMOR-ASSOCIATED IMMUNOSUPPRESSION
Immunosuppression in the tumor microenvironment is a daunt-
ing obstacle that limits the success of current tumor immunother-
apy (Singh and Paterson, 2007b; Duraiswamy et al., 2013). It is
mediated by a number of suppressive cell types such as Tregs
and signaling molecules that limit immune effector cell function
(Hussain and Paterson, 2004; Blank et al., 2005). Interestingly,
Lm-based vaccines alone canmitigate tumor-associated immuno-
suppression (Wallecha et al., 2013a). Hussein and Paterson
demonstrated that Tregs are significantly decreased upon admin-
istration of Lm-based vaccines that secrete TAAs fused to trun-
cated LLO (Hussain and Paterson, 2004). Tregs in the tumor
microenvironment produce anti-inflammatory cytokines such as
IL-10 and TGF-β that impair T cell responses and directly inhibit
the function of APCs through interaction with the inhibitory
receptor, CTLA-4 (Wing et al., 2008). Unexpectedly, an iso-
genic Lm-based vaccine that expressed and secreted only the
TAA actually increased the number of Tregs within the tumor
microenvironment and demonstrated reduced anti-tumor effi-
cacy (Gunn et al., 2001). Therefore, it is possible that the PAMP-
like activity of dtLLO is a major contributor to the reduction
of tumor-associated immunosuppression by Lm-based vaccines.
Subsequent studies have additionally confirmed this reduction in
the number of tumor-associated Tregs after Lm-based vaccination
(Guirnalda et al., 2013). In addition to Tregs, myeloid-derived
suppressor cells (MDSCs) can also mediate immunosuppression
in tumor-bearing patients (Almand et al., 2001). MDSCs produce
anti-inflammatory cytokines and work in concert with Tregs to
inhibit CTL responses (Yang et al., 2006). Production and secre-
tion of peroxinitrite by MDSCs results in direct modification of
the TCRs of tumor-infiltrating CTLs and limit their ability to
recognize MHC Class I presented TAA peptides (Nagaraj et al.,
2007). In recent work by Wallecha and colleagues, Lm-based
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vaccines expressing dtLLO-fused antigens reduced not just the
number of tumor-infiltrating MDSCs and Tregs but also reduced
their suppressive activity (Wallecha et al., 2013a). This find-
ing of reduced tumor-infiltrating MDSCs and Tregs after Lm-
based immunotherapy was also confirmed in a recent study by
Mkrtichyan et al. (2013).
In addition to suppressive cell types in tumors, the func-
tion of tumor-specific infiltrating CTLs can also be hampered by
expression and ligation of inhibitory receptors on their surface.
One common inhibitory receptor expressed on tumor-infiltrating
CTLs is programmed death 1 (PD-1), which is activated by its lig-
ands PD-L1 and PD-L2 expressed by tumor cells (Liu et al., 2003;
Blank et al., 2005). Activation of PD-1 on T cells results in their
gradual loss of function as demonstrated by reduced proinflam-
matory cytokine production and lytic activity (Wherry, 2011).
Interestingly, in a recent study by Yoshimura et al, Lm-vaccine
treatment resulted in reduced expression of PD-1 by CD8+ T cells
in the metastases-bearing livers of mice (Olino et al., 2012). A
similar downregulation was not observed on CD8+ T cells in sec-
ondary lymphoid organs of the same mice, however, suggesting
that this effect was metastases and/or tumor-specific.
HIGHLY ATTENUATED BUT IMMUNOGENIC Lm VACCINE STRAINS
In order to develop Lm vaccines for the clinic, the use of viru-
lent strains of the pathogen would be unacceptable for patients
that are already likely in an immunosuppressed state (Golub et al.,
1974). Fortunately, there are established methods of Lm attenua-
tion that may not only increase their safety profile but actually
enhance immunogenicity of antigens expressed by Lm.
Deletion of Lm virulence genes
In order to accomplish stable attenuations of Lm vaccine strains,
groups have employed strains containing deletions of genes
involved in Lm virulence. The most common Lm vaccine strain,
XFL-7, lacks the Lm transcriptional activator PrfA (Gunn et al.,
2001). PrfA regulates the expression of numerous virulence fac-
tors such as LLO, therefore, strains lacking the prfA gene are
highly attenuated due to their inability to escape into the cytosol
and avoid phagolysosomal destruction (Freitag et al., 1993).
However, in order to generate robust CTL responses, an effec-
tive Lm vaccine strain must gain access to the cytosol to deliver
antigens. Therefore, XFL-7-based Lm vaccines are transformed
with episomal plasmids encoding the prfA gene along with an
antigen (Gunn et al., 2001). The introduction of this episomal
plasmid complements the deficiency in prfA, however, the expres-
sion is not sufficient for XFL-7 to regain full virulence and is,
therefore, attenuated. Subsequent studies have focused on the
development of Lm strains with more targeted deletion of viru-
lence factors that are not required for the development of robust
immune responses. One such virulence gene, actA, is not neces-
sary for the initial infection of Lm into a host cell or entry into
the cytosol but is required for cell-to-cell spread of the bacterium
(Brockstedt et al., 2004). While ActA-specific immunity is observ-
able after an Lm infection, these responses are dispensable to the
clearance of the bacterium, likely due to the membrane-bound
nature of ActA hampering MHC Class I accessibility (Darji et al.,
1998). Deletion of actA results in a highly attenuated Lm strain
with an LD50 of 2× 108 CFUs as compared to 105 CFUs by wild-
type Lm while still retaining immunogenicity (Brundage et al.,
1993; Starks et al., 2004). In fact, actA-deficient Lm expressing
the model tumor antigen, chicken ovalbumin (OVA), is able to
induce a more effective anti-tumor response than a wild-type
strain of Lm expressing the same antigen (Starks et al., 2004).
Therefore, attenuation of Lm may not just serve the purpose
of improving its safety profile but it is also a rational strat-
egy to increase immunogenicity to Lm-expressed TAAs. Further
advancement in the development of attenuated Lm vaccine strains
by Brockstedt and colleagues employed deletion of an additional
virulence gene, internalin B (inlB) in an actA-deficient Lm strain
(Brockstedt et al., 2004). The rationale for the deletion of inlB
in this background was to construct a vaccine vector that exclu-
sively infects antigen-presenting cells as InlB mediates infection
of non-phagocytic cells (Gaillard et al., 1991). This was sought as
a strategy to minimize toxicity from the infection, especially to
the liver where toxicity is observed due to Lm infection of hep-
atocytes, while maximizing uptake of the vector to professional
phagocytic antigen-presenting cells. Deletion of inlB in an actA
deficient strain led to reduced capacity to infect both mouse and
primary human hepatocytes and enhanced clearance from the
liver of infected mice in comparison to a wild-type strain and
the actA only deficient strain. Furthermore, deletion of inlB in
the actA deletion strain that expressed the murine colon TAA,
gp70, resulted in increased immunogenicity in comparison to
actA deficiency alone as observed by significantly greater gp70-
specific CTL responses, reduced metastatic burden with CT26
colon carcinoma tumors, and increased survival (Olino et al.,
2012). The impressive immunogenicity and efficacy of the plcB
actA Lm vaccine strain preclinically has led to its introduc-
tion into clinical trials for multiple cancers (Le et al., 2012).
However, the deletion of a virulence gene such as inlB to limit
infection of non-phagocytic cells may be eliminating additional
mechanisms of anti-tumor efficacy by Lm-based vaccines (Kim
et al., 2009). In addition to inlB, other studies have focused on
deletion of plcB, another virulence gene of Lm encoding phos-
pholipase C (PC-PLC), in the background of an actA deficient
Lm vaccine strain (Angelakopoulos et al., 2002). PC-PLC is the
broad-range phospholipase C of Lm that plays an important role
in the breakdown of double-membrane vacuoles encountered
during cell-to-cell spread by Lm (Vazquez-Boland et al., 1992;
Smith et al., 1995). Deletion of plcB results in a highly attenuated
Lmwith reduced ability to spread cell-to-cell but also reduced tox-
icity as intracerebral infection is greatly reduced (Schluter et al.,
1998). Deletion of both plcB and actA still allows for the induc-
tion of robust T cell responses in mouse models (Darji et al.,
2003; Lenz et al., 2008) and a plcB actA strain has demon-
strated safety in a human clinical trial (Angelakopoulos et al.,
2002).
Killed but metabolically active (KBMA) Lm
One of the earliest methods for safely inducing prophylactic
immunity to pathogens was through the use of inactivated or
killed forms of the same pathogen, commonly through heating
(Smith and Little, 1926). While this method of inactivation is suf-
ficient for induction of humoral responses to pathogen-associated
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immunogens, it is an ineffective approach to induce CTL-
mediated immunity against Lm-derived antigens (Schafer et al.,
1992). This lack of CTL-mediated immunity with heat-killed Lm
(HKLM) is likely due in part to an inability to escape from the
phagosome into the cytosol to deliver antigens to the MHC Class
I pathway (Brunt et al., 1990). Additionally, a study by Bahjat et al.
demonstrates that HKLM infection can also actively suppress
cell-mediated immunity through induction of IL-10 in a MyD88-
dependent manner (Bahjat et al., 2009). Therefore, a newmethod
of inactivation was developed to provide the safety advantages of
a killed vaccine but also maintain efficient delivery of antigens
to the MHC Class I presentation machinery and induce the nec-
essary inflammatory responses to provide immunogenicity. This
new type of inactivation produced an Lm that was killed but
metabolically active (KBMA) (Brockstedt et al., 2005; Skoberne
et al., 2008). In order to achieve this method of inactivation, a
recombinant vaccine strain of Lm that contains deletions of the
uvrAB genes involved in nucleotide excision repair is treated with
the DNA-intercalating agent psoralen and then DNA-psoralen
crosslinking is induced with exposure to UV irradiation. The
result is a bacterium that is unable to replicate and is functionally
killed due to DNA crosslinking but still able to transcribe encoded
genes and produce and secrete protein antigen. Importantly,
KBMA Lm is also capable of escaping from phagosomes and deliv-
ering secreted antigens to the cytosol for MHC Class I processing
and presentation (Dubensky et al., 2012). Vaccination with a
KBMA Lm targeting a model TAA has also been shown provide
comparable anti-tumor efficacy to a live-attenuated Lm strain
but with slightly reduced antigen-specific CD8+ T cell responses
(Skoberne et al., 2008).
METHODS FOR THE EXPRESSION OF FOREIGN ANTIGENS BY Lm
Expression of antigens by Lm can be of episomal origin, but
expression can also be from the Lm chromosome. Plasmid-based
strategies have the advantage of multicopy expression, which may
be more efficacious in terms of the amount of antigen protein
expressed, but rely on complementation for the maintenance of
the plasmid in vivo. The retention of plasmid by Lm in vivo in
one engineered Listeria strain is achieved by the complementation
of the prfA gene from the plasmid in a prfA negative mutant Lm
background (Gunn et al., 2001). Without prfA complementation,
this mutant Lm cannot escape the phagosome and is destroyed by
macrophages and neutrophils. As a result, it cannot grow intracel-
lularly or present antigens to the immune system. In early studies
it was found that including a copy of prfA in the plasmid ensures
the in vivo retention of the plasmid in Lm (Pan et al., 1995a,b).
Another approach is based on the in vitro and in vivo comple-
mentation of D-alanine racemase in both E. coli and Lm strains
deficient in D-alanine racemase (dal) and D-alanine amino trans-
ferase (dat) (Verch et al., 2004; Wallecha et al., 2009; Shahabi
et al., 2011). This Lm vaccine strain, Lmdd, has the advantage
that it is devoid of antibiotic selectionmarkers. In order to further
improve the safety profile of Lmdd, current constructs contain a
deletion of the virulence gene actA resulting in the LmddA strain
(Wallecha et al., 2009; Ishizaki et al., 2010).
Chromosomal integration techniques can utilize either a
phage-based system, with a site-specific integrase to integrate a
gene into the genome (Camilli et al., 1993; Lauer et al., 2002) or
allelic exchange into a known chromosomal locus (Gunn et al.,
2001; Mata et al., 2001). Recombinant strains based on chromo-
somal integration have been shown to be somewhatmore virulent
(Gunn et al., 2001) than similar episomal recombinants and are
thus less suitable to be used as human vaccines backbones with-
out further attenuation. This has been achieved by the deletion of
virulence genes such as actA and inlB from the Lm chromosome,
which in combination limit Lm growth in the liver, a principal
target organ of infection by the wild type organism (Brockstedt
et al., 2004).
Lm TROPISM FOR PRIMARY AND METASTATIC TUMORS
One of the most promising aspects of Lm as a live vaccine
vector is its ability to specifically target and thrive within pri-
mary and metastatic tumor lesions. Initially documented by Yu
et al., recent work has confirmed the tumor-homing proper-
ties of Lm (Yu et al., 2004; Kim et al., 2009; Quispe-Tintaya
et al., 2013). In a study by Gravekamp and colleagues, an Lm-
based vaccine delivering a portion of the melanoma-associated
antigen (MAGE)-b TAA, Lm-LLO-Mage-b311-660, along with
an empty vector control, Lm-LLO, were found to infect both
the murine 4T1 mammary carcinoma cell line and the human
MCF7 breast tumor cell line in vitro (Kim et al., 2009). In vivo,
Lm-LLO-Mage-b311-600 accumulated in primary 4T1 breast
tumors as well as 4T1 metastatic lesions in the lungs and lymph
nodes of tumor-bearing mice. Infection of tumor cells by each
attenuated Lm construct resulted in cell death by activation of
NADPH oxidase and elevated levels of cytosolic reactive oxida-
tive species (ROS). A more recent study by the same laboratory
documented a similar tumor-homing ability of an attenuated Lm
vector that expresses truncated LLO from an episomal plasmid
(Listeriaat) to pancreatic tumors in mice (Quispe-Tintaya et al.,
2013). Listeriaat tropism was specific for primary tumors and
metastatic lesions with very little accumulation in normal tissues
three days after infection. In fact, Listeriaat appeared to be selec-
tive for the metastatic lesions of Panc-02 pancreatic tumor cells.
To leverage this tumor tropism therapeutically, radioactively-
labeled Listeriaatwas administered to tumor-bearing mice. The
radioactively-labeled Listeriaat markedly reduced the number of
Panc-02 metastatic lesions in tumor-bearing mice demonstrat-
ing the potential of attenuated Lm constructs as tumor-targeting
vectors (Quispe-Tintaya et al., 2013).
Lm AS AN EFFECTIVE VACCINE VECTOR FOR TUMOR
IMMUNOTHERAPY: PRECLINICAL STUDIES TARGETING
CLINICALLY RELEVANT TAAs
Lm-based vaccines have been developed for numerous malignan-
cies that demonstrate promising efficacy in preclinical models
of cancer. Several of these vaccines, grouped by indication, are
described in detail below and listed in Table 1.
CERVICAL CANCER
Early studies demonstrated the ability of Lm-based immunother-
apies to induce therapeutically effective CTL responses against
viral antigens in both an infection setting or when utilized as
a model tumor antigen (Schafer et al., 1992; Ikonomidis et al.,
Frontiers in Cellular and Infection Microbiology www.frontiersin.org May 2014 | Volume 4 | Article 51 | 8
Wood and Paterson Listeria monocytogenes as a vector for tumor immunotherapy
Ta
b
le
1
|L
m
-b
as
ed
va
cc
in
es
in
d
ev
el
o
p
m
en
t
th
at
ta
rg
et
cl
in
ic
al
ly
-r
el
ev
an
t
tu
m
o
r-
as
so
ci
at
ed
an
ti
ge
n
s.
Ta
rg
et
Ta
rg
et
an
ti
ge
n
Lm
-b
as
ed
V
ac
ci
n
e
Lm
-s
tr
ai
n
Lm
-e
xp
re
ss
ed
A
n
ti
ge
n
R
ef
er
en
ce
s
C
er
vi
ca
lc
an
ce
r
H
P
V
16
E
7
Lm
-E
7
10
40
3S
(w
t)
LL
O
si
gn
al
se
qu
en
ce
fu
se
d
to
H
P
V
16
E
7
G
un
n
et
al
.,
20
01
H
P
V
16
E
7
Lm
-L
LO
-E
7
(A
D
X
S
-H
P
V
)
X
FL
-7
(p
rf
A
-)
dt
LL
O
fu
se
d
to
H
P
V
16
E
7
G
un
n
et
al
.,
20
01
H
P
V
16
E
7
rL
m
-E
7
10
40
3S
(w
t)
H
P
V
16
E
7
fu
se
d
at
th
e
N
-t
er
m
in
us
w
ith
th
e
LL
O
si
gn
al
se
qu
en
ce
an
d
at
th
e
C
-t
er
m
in
us
w
ith
E
.c
ol
iP
ho
A
Li
n
et
al
.,
20
02
H
P
V
16
E
7
Lm
-A
ct
A
-E
7
X
FL
-7
(p
rf
A
-)
A
ct
A
a.
a.
1-
42
0
fu
se
d
to
H
P
V
16
E
7
S
ew
el
le
t
al
.,
20
04
a
H
P
V
16
E
7
Lm
-P
E
ST
-E
7
X
FL
-7
(p
rf
A
-)
LL
O
a.
a.
1-
50
fu
se
d
to
H
P
V
16
E
7
S
ew
el
le
t
al
.,
20
04
b
H
P
V
16
E
7
Lm
-v
1
an
d
v2
Lm
dd
(d
al
-d
at
-)
dt
LL
O
fu
se
d
to
H
P
V
16
E
7
ex
pr
es
se
d
fr
om
a
pC
M
V-
dr
iv
en
pl
as
m
id
de
liv
er
ed
by
Lm
S
ou
de
rs
et
al
.,
20
06
C
R
P
V
E
1
E
1-
rL
m
10
40
3S
(w
t)
C
R
P
V
E
1
fu
se
d
at
th
e
N
-t
er
m
in
us
w
ith
th
e
LL
O
si
gn
al
se
qu
en
ce
an
d
at
th
e
C
-t
er
m
in
us
w
ith
E
.c
oi
lP
ho
A
Je
ns
en
et
al
.,
19
97
B
re
as
t
ca
nc
er
R
at
H
er
2/
ne
u
Lm
-L
LO
-E
C
1,
E
C
2,
E
C
3,
IC
1,
an
d
IC
2
X
FL
-7
(p
rf
A
-)
dt
LL
O
fu
se
d
to
se
le
ct
ed
re
gi
on
s
of
ra
t
H
er
2/
ne
u
S
in
gh
et
al
.,
20
05
H
um
an
H
er
2/
ne
u
Lm
-h
H
er
2/
ne
u
ch
im
er
a
X
FL
-7
(p
rf
A
-)
dt
LL
O
fu
se
d
to
ch
im
er
ic
pr
ot
ei
n
co
nt
ai
ni
ng
ep
ito
pe
s
fr
om
hu
m
an
H
er
2/
ne
u
S
ea
ve
y
et
al
.,
20
09
b
H
um
an
H
er
2/
ne
u
Lm
-c
H
er
2
(A
D
X
S
-c
H
E
R
2)
Lm
dd
A
(d
al
-d
at
-a
ct
A
-)
dt
LL
O
fu
se
d
to
ch
im
er
ic
pr
ot
ei
n
co
nt
ai
ni
ng
ep
ito
pe
s
fr
om
hu
m
an
H
er
2/
ne
u
S
ha
ha
bi
et
al
.,
20
11
M
ou
se
IS
G
15
Lm
-L
LO
-IS
G
15
X
FL
-7
(p
rf
A
-)
dt
LL
O
fu
se
d
to
m
ou
se
IS
G
15
W
oo
d
et
al
.,
20
12
M
ou
se
M
A
G
E
-b
Lm
LL
O
M
ag
e-
b 3
11
−6
60
X
FL
-7
(p
rf
A
-)
dt
LL
O
fu
se
d
to
m
ou
se
M
ag
e-
b
a.
a.
31
1-
60
0
K
im
et
al
.,
20
08
H
um
an
p5
3
Lm
dd
A
-L
LO
-p
53
Lm
dd
A
(d
al
-d
at
-a
ct
A
-)
dt
LL
O
fu
se
d
to
hu
m
an
p5
3
Is
hi
za
ki
et
al
.,
20
10
Tu
m
or
-a
ss
oc
ia
te
d
va
sc
ul
at
ur
e
M
ou
se
V
E
G
FR
-2
(F
lk
-1
)
Lm
-L
LO
-F
lk
-E
1,
E
2,
an
d
l1
X
FL
-7
(p
rf
A
-)
dt
LL
O
fu
se
d
to
se
le
ct
ed
re
gi
on
s
of
m
ou
se
V
E
G
FR
-2
(F
lk
-1
)
S
ea
ve
y
et
al
.,
20
09
a
H
um
an
H
M
W
-M
A
A
Lm
-L
LO
-H
M
W
M
A
A
-C
X
FL
-7
(p
rf
A
-)
dt
LL
O
fu
se
d
to
hu
m
an
H
M
W
-M
A
A
a.
a.
21
60
-2
25
8
M
ac
ia
g
et
al
.,
20
08
M
ou
se
C
D
10
5
(e
nd
og
lin
)
Lm
-L
LO
-C
D
10
5A
an
d
B
X
FL
-7
(p
rf
A
-)
dt
LL
O
fu
se
d
to
se
le
ct
ed
re
gi
on
s
of
m
ou
se
C
D
10
5
(e
nd
og
lin
)
W
oo
d
et
al
.,
20
11
M
el
an
om
a
M
ou
se
TR
P
2,
LC
M
V
N
P
Lm
-T
R
P
2-
N
P
10
40
3S
(w
t)
M
ou
se
TR
P
2
a.
a.
24
-1
91
fu
se
d
at
th
e
N
-t
er
m
in
us
w
ith
th
e
LL
O
si
gn
al
se
qu
en
ce
an
d
at
th
e
C
-t
er
m
in
us
w
ith
LC
M
V
N
P
a.
a.
17
7-
19
1
fo
llo
w
ed
by
E
.c
ol
iP
ho
A
B
ru
hn
et
al
.,
20
05
M
ou
se
TR
P
2
Lm
-T
R
P
2
10
40
3S
(w
t)
M
ou
se
TR
P
2
a.
a.
24
-1
91
fu
se
d
at
th
e
N
-t
er
m
in
us
w
ith
th
e
LL
O
si
gn
al
se
qu
en
ce
an
d
at
th
e
C
-t
er
m
in
us
w
ith
E
.
co
li
P
ho
A
B
ru
hn
et
al
.,
20
05
H
um
an
H
M
W
-M
A
A
Lm
-L
LO
-H
M
W
M
A
A
-C
X
FL
-7
(p
rf
A
-)
dt
LL
O
fu
se
d
to
hu
m
an
H
M
W
-M
A
A
a.
a.
21
60
-2
25
8
M
ac
ia
g
et
al
.,
20
08
Pr
os
ta
te
ca
nc
er
H
um
an
P
SA
Lm
-L
LO
-P
SA
X
FL
-7
(p
rf
A
-)
dt
LL
O
fu
se
d
to
hu
m
an
P
SA
S
ha
ha
bi
et
al
.,
20
08
H
um
an
P
SA
A
D
V
X
-3
1-
14
2
(A
D
X
S
-P
SA
)
Lm
dd
A
(d
al
-d
at
-a
ct
A
-)
dt
LL
O
fu
se
d
to
hu
m
an
P
SA
W
al
le
ch
a
et
al
.,
20
09
H
ep
at
oc
el
lu
la
r
ca
rc
in
om
a
H
B
c,
H
B
V-
X
,
H
um
an
al
ph
a-
Fe
to
pr
ot
ei
n,
an
d
H
um
an
M
A
G
E
-A
Lm
-M
P
FG
Lm
dd
(d
al
-d
at
-)
dt
LL
O
fu
se
d
to
a
fu
si
on
pe
pt
id
e
co
nt
ai
ni
ng
fu
ll-
le
ng
th
H
B
c,
H
B
x
a.
a.
52
-6
0,
H
B
x
a.
a
14
0-
14
8,
A
FP
a.
a
15
8-
16
6,
M
A
G
E
a.
a.
27
1-
27
9
an
d
a
fla
g
ta
g
C
he
n
et
al
.,
20
12
Frontiers in Cellular and Infection Microbiology www.frontiersin.org May 2014 | Volume 4 | Article 51 | 9
Wood and Paterson Listeria monocytogenes as a vector for tumor immunotherapy
1994, 1997; Pan et al., 1995a,b; Shen et al., 1995; Slifka et al.,
1996; Jensen et al., 1997; Mata et al., 1998; Mata and Paterson,
1999). These studies provided the rationale to target Lm-based
immunotherapies against virus-induced cancers. Cervical can-
cer is one of the most common forms of virus-induced cancer
being the result of chronic infection with a transforming strain of
human papillomavirus (HPV) (Cutts et al., 2007). It is especially
prevalent among those with an active infection with a high-
risk form of HPV, such as HPV16 or HPV18. HPV infection of
mucosal epithelium tissue results in papilloma formation through
the action of eight encoded proteins that are either expressed early
in an infection to facilitate replication of HPV DNA with the E1,
E2, E3, E4, E5, and E6 proteins or late in an infection to form
the viral capsid with the L1 and L2 proteins. It is the early genes,
E6 and E7 in particular, that allow for the papillomas to become
malignant due to their inhibition of tumor suppressor genes, p53
and Rb respectively (Moody and Laimins, 2010). HPV E6 and E7
are constitutively expressed in the vast majority of cervical can-
cers caused by HPV infection due to their integration into the
host genome and E7 is necessary for maintaining the malignant
state of the tumor cells (Jabbar et al., 2012). It is for this reason
that E6 and E7 make ideal targets for therapeutic strategies and
why much of the effort to develop Lm-based immunotherapies
for cervical cancer have focused specifically on targeting HPV E7.
HPV16 E7
The first study to apply recombinant Lm vaccine technology to a
therapeutically relevant model of cancer in mice was performed
by the Paterson laboratory and published in 2001 (Gunn et al.,
2001). To develop their Lm-based therapeutics for cervical cancer,
the group utilized a mouse model for HPV-induced malignancy,
the TC.1 tumor model (Lin et al., 1996). The strategy for devel-
oping the first Lm-based immunotherapies was to engineer two
separate recombinant Lm strains with each expressing HPV16 E7
due to its broad expression among all ano-genital malignancies
(Gunn et al., 2001). However, one recombinant Lm expressed and
secreted E7 alone, Lm-E7, while another strain was developed that
expressed and secreted HPV16 E7 genetically fused to dtLLO, Lm-
LLO-E7. After implanting TC.1 tumors in mice and allowing for
establishment, mice were administered either vaccine and tumor
growth monitored. While each E7-secreting vaccine successfully
delayed tumor growth in comparison to untreated or control Lm
treated mice, only Lm-LLO-E7 resulted in complete eradication
of established tumors. Surprisingly, the increased anti-tumor effi-
cacy of Lm-LLO-E7 in comparison to Lm-E7 was not the result of
greater induction of E7-specific CTL responses in peripheral lym-
phoid organs as each vaccine was just as effective. Further studies
determined that vaccination with Lm-E7 resulted in induction of
greater numbers of CD4+ Tregs. In fact, it appeared that much
of the reduced efficacy of Lm-E7 in comparison to Lm-LLO-E7
was due to Treg-mediated suppression of anti-tumor immune
responses as Treg-depletion resulted in comparable anti-tumor
responses. These results were confirmed in a subsequent study
demonstrating that Lm-E7 preferentially induces Tregs that sup-
press effector cell function through production of IL-10 and
TGF-β (Hussain and Paterson, 2004). Furthermore, work by Peng
et al. found that Lm-LLO-E7 infection of BMDCs resulted in
greater BMDC maturation, IL-2 production, and expansion of
E7-specific CTLs than Lm-E7 infection (Peng et al., 2004). Lin
et al provided additional evidence of the benefit of this approach
in a study that reported significant anti-tumor protective immu-
nity after vaccination with an Lm-based construct, rLm-E7, that
secreted E7 fused to both a portion of LLO and E. coli phoA (Lin
et al., 2002). These studies demonstrate the promising therapeutic
potential of Lm-based vaccines against cervical cancer but provide
caution to others with the evidence that therapeutic vaccines may
also induce peripheral tolerance if constructed improperly.
Previous studies have found that expression of HPV16 E7 can
result in loss of responsiveness to IFN-γ (Park et al., 2000; Zhou
et al., 2011). While this lack of responsiveness may be a resis-
tance mechanism to limit the direct anti-viral and anti-tumor
effect of IFN-γ, studies have suggested it may also impact anti-
tumor immune responses (Beatty and Paterson, 2000, 2001). In
fact, the initial study with Lm-LLO-E7 by Gunn et al. determined
that the anti-tumor efficacy of Lm-LLO-E7 was dependent on
the effects of IFN-γ (Gunn et al., 2001). To determine the role
of IFN-γ in the anti-tumor response mediated by Lm-LLO-E7,
Dominiecki et al utilized a TC.1 variant cell line unresponsive
to IFN-γ due to constitutive expression of a dominant negative
form of the IFN-γ receptor, termed mugR (Dominiecki et al.,
2005). While TC.1-mugR tumors grew slightly slower than TC.1
parental tumors in the absence of therapy, they were resistant to
the anti-tumor response mediated by Lm-LLO-E7. The mech-
anism for this resistance to Lm-LLO-E7 therapy appeared to
correspond to the inability of CTLs to migrate into the tumor
and effect tumor regression. Paterson and colleagues studied this
phenotype further and discovered that IFN-γ stimulation of TC.1
tumor cells results in the production of a chemokine, CXCL9,
that mediates infiltration of CD8+ T cells into TC.1 tumors after
Lm-LLO-E7 vaccination (Guirnalda et al., 2013). Therefore, the
effective anti-tumor immune response induced by Lm-LLO-E7
is due to a number of factors such as reduced peripheral toler-
ance and increased maturation of dendritic cells but this response
is only effective if tumors remain compliant through responsive-
ness to IFN-γ, a determinant that may be useful to predict patient
outcomes with Lm-based immunotherapies.
Numerous studies have found that responses to tumor
immunotherapy are greatly enhanced when mechanisms main-
taining peripheral tolerance are inhibited (Gunn et al., 2001;
Duraiswamy et al., 2013; Mkrtichyan et al., 2013). While there are
several pathways regulating peripheral tolerance, the PD-1 recep-
tor pathway is gaining particular interest as a target for improving
immunotherapies (Topalian et al., 2012). Interestingly, BMDCs
infected with Lm-LLO-E7 were found to upregulate expression
of the PD-1 ligand, PD-L1 (Peng et al., 2004; Mkrtichyan et al.,
2013). Therefore, Khleif and colleagues sought to determine if
activation of the PD-1 immune inhibitory pathway was limiting
the efficacy of Lm-LLO-E7 (Mkrtichyan et al., 2013). Antibody-
mediated blockade of PD-1 along with Lm-LLO-E7 did result
in increased anti-tumor efficacy as determined by TC.1 tumor
load, survival, and E7-specific T cell responses in comparison
to vaccine alone. However, the Lm-LLO-E7 dose in this study
was approximately 20-fold lower (5× 106 CFUs) than in previ-
ous studies (108 CFUs) so it is unclear if this enhanced efficacy is
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only evident when given with a suboptimal dosage of Lm-LLO-
E7 (Gunn et al., 2001; Guirnalda et al., 2013). Nevertheless, the
results obtained from this study could lead to a very effective syn-
ergistic clinical treatment regimen especially with the promising
results of both Lm-LLO-E7 and anti-PD-1 treatment separately in
clinical trials (Maciag et al., 2009; Petit and Basu, 2013; Topalian
et al., 2012).
BREAST CANCER
Her2/neu
After finding preclinical success treating models of virus-induced
cancer, development progressed on Lm-based vaccines for other
challenging indications such as breast cancer where the only iden-
tified targets are self-TAAs, such as Her2/neu. Her2 is a epidermal
growth factor receptor family protein that is overexpressed in
roughly 25% of human breast tumors and correlates with poor
prognosis (Slamon et al., 1987). While most vaccines targeting
Her2 were primarily used in prophylactic settings, Singh et al
rationalized that the use of Lm as a vaccine vector may induce
a robust CTL response that is therapeutically effective (Singh
et al., 2005). However, in order to construct Lm-based vaccines
against a large membrane-bound receptor like Her2, several con-
structs were required to be developed. Each construct contained
a portion of the intracellular (Lm-LLO-IC1 and Lm-LLO-IC2)
or the extracellular (Lm-LLO-EC1, Lm-LLO-EC2 and Lm-LLO-
EC3) portion of the full-length rat Her2/neu protein to allow for
efficient production and secretion by Lm. Therapeutic vaccina-
tion with each of the constructs individually resulted in reduced
or static growth of NT-2 breast tumors, a tumor cell that constitu-
tively expresses rat Her2/neu under the mouse mammary tumor
virus (MMTV) promoter (Singh et al., 2005). In comparison to
DNA vaccines targeting Her2, Lm-based vaccines demonstrated
significantly greater therapeutic efficacy. Interestingly, the efficacy
of Lm-based Her2 vaccines was not due solely to the bacterium
as a DNA vaccine study suggested the fusion of the Her2 anti-
genic regions to dtLLO is also an important factor (Singh and
Paterson, 2006b). The mechanism for this improved efficacy of
Lm or LLO-based Her2 vaccines appears to be in their ability to
induce a greater repertoire of Her2-specific CTLs. In fact, vacci-
nation with Lm-based Her2 vaccines also revealed more epitopes
than had been previously identified with a DNA vaccination strat-
egy (Singh et al., 2005). This suggests that vaccination against
Her2 with Lm or LLO-based vaccines generated both a quantita-
tively and qualitatively different response than by other methods
and with greater therapeutic efficacy.
While initial studies with the Lm-Her2 vaccines demonstrated
promising efficacy against a mouse tumor cell line that expresses
rat Her2/neu, they were performed in amousemodel that was not
fully tolerant to the antigen. Although rat and mouse Her2/neu
are roughly 94% homologous, rat Her2/neu is immunogenic in
mice (Nagata et al., 1997). Therefore, future studies were per-
formed in an MMTV-Her2/neu-transgenic mouse model that
constitutively expresses rat Her2/neu under control of theMMTV
promoter and shows profound tolerance to rat Her2/neu (Guy
et al., 1992; Reilly et al., 2000). Although fewer mice responded
to Lm-Her2 therapy, complete tumor regressions were observed.
Further studies elucidated several mechanisms for the vaccines
not reaching their full therapeutic potential. First, after vacci-
nation with Lm-Her2 vaccines, tumors would undergo immu-
noediting, a process wherein immunological pressure against a
TAA will result in selective outgrowth of tumor cells that have
mutations in the targeted antigen (Singh and Paterson, 2007a).
Second, central tolerance to self-TAAs, in particular for these
studies with Her2, is detrimental to the induction of high avidity
tumor-specific CTLs (Singh and Paterson, 2007b). When FVB/N
Her2/neu transgenic mice bearing Her2-positive tumors were
vaccinated with Lm-based Her2 vaccines, CTLs were generated
against previously revealed epitopes but the avidity of those CTLs
was reduced by at least one log in comparison to CTLs gener-
ated in a wild-type mouse. Finally, peripheral tolerance mediated
by suppressive cell types such as Tregs also limits the efficacy of
Lm-based tumor immunotherapies (Singh and Paterson, 2007b).
Antibody-mediated depletion of Tregs concomitant with Lm-
based vaccination against Her2 resulted in enhanced anti-tumor
efficacy, therefore, providing a possible therapeutic avenue for
improved efficacy in the clinic (Singh and Paterson, 2007b).
To translate the success of Lm-based immunotherapies target-
ing rat Her2/neu into the clinic, development of several vaccines
was undertaken that expressed regions or defined epitopes within
human Her2 (Seavey et al., 2009b; Shahabi et al., 2011). As in
the previous studies with rat Her2/neu, Lm-based vaccines were
developed that expressed separate regions of the intracellular
(Lm-LLO-hIC1) and extracellular (Lm-LLO-hEC1 and Lm-LLO-
hEC2) portions of human Her2. Due to the high degree of
homology between human and rodent Her2/neu and the pres-
ence of defined H-2q epitopes within the portions from human
Her2 (Seavey et al., 2009b), mouse breast tumor models such
as NT-2, 4T1, and the MMTV-Her2/neu transgenic could be
used to assess efficacy. Each of these vaccines was found to be
equally as effective at inducing Her2/neu-specific CTL responses
and controlling tumor growth in each of the tumor models as
the previous rat Her2/neu-based constructs. However, to improve
the breadth of the immune response against Her2, an additional
vaccine was developed that contained most of the HLA epitopes
found within Lm-LLO-hIC1, Lm-LLO-hEC1, and Lm-LLO-hEC2
but expressed as a single polyvalent antigen (Seavey et al., 2009b).
This chimeric Her2 vaccine, named Lm-hHer2/neu chimera,
demonstrated significant anti-tumor efficacy and was able to
delay autochthonous tumor formation in a tolerized Her2/neu
transgenic mouse. Additionally, the Lm-hHer2/neu chimera was
able to prevent lung metastasis formation from intravenous chal-
lenge with the highly aggressive 4T1-Luc breast tumor model.
This impressive efficacy of Lm-hHer2/new chimera at eliciting
a potent anti-tumor response was highlighted by the relatively
low expression of Her2/neu by 4T1-Luc tumor cells (Seavey
et al., 2009b). The success of the Lm-hHer2/neu chimera vaccine
resulted in its further development into a new Lm-based vector
that is absent of any antibiotic resistance genes, and is there-
fore more easily translatable to the clinic (Shahabi et al., 2011).
This new vaccine, ADXS-cHER2, demonstrated improved effi-
cacy over Lm-hHer2/neu chimera in autochthonous Her2/neu
breast tumor studies but also an impressive ability to protect mice
from intracranial challenge from the EMT6-Luc breast tumor
cell line. The preclinical development of Lm-based chimeric Her2
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vaccines predicts a promising future that will be determined in
clinical trials that are ongoing in canines and currently planned
for humans (Figure 3).
Interferon stimulated gene 15 (ISG15)
While Her2 is a promising target for breast cancer tumor
immunotherapy, its wide application is limited since only about
25% of breast cancer patients have elevated expression of Her2
in their tumors (Slamon et al., 1987). This is especially problem-
atic for breast cancer patients with tumors that lack expression
of Her2/neu, progesterone receptor, and the estrogen receptor,
denoted as triple-negative, and have few therapeutic options
available (Hudis and Gianni, 2011). Therefore, the discovery
of novel TAAs for use in breast tumor immunotherapy is a
desired goal. Progress in this area of research was recently
reported in a study that targeted a small ubiquitin-like pro-
tein elevated in even triple-negative breast tumors, ISG15, with
an Lm-based immunotherapy (Bektas et al., 2008; Wood et al.,
2012). After validating overexpression of ISG15 in mouse mod-
els of breast cancer and developing an Lm-based vaccine that
expresses ISG15 fused to dtLLO, Wood et al found that vac-
cination of mice with Lm-LLO-ISG15 resulted in induction of
ISG15-specific CTL responses. In a therapeutic setting, treat-
ment with Lm-LLO-ISG15 significantly reduced the growth of
breast tumors and the number of metastatic lesions in the lungs
of tumor-bearing mice. When administered prophylactically in
MMTV-Her2/neu transgenic mice, autochthonous mammary
tumor formation was significantly delayed as compared to a con-
trol Lm. These results suggest that ISG15 is not only a novel
immunotherapeutic target for breast cancer but also that Lm-
based vaccines are powerful platforms to validate TAA discovery.
Melanoma-associated antigen (MAGE)-b
MAGE are a type of cancer/testis antigens commonly targeted in
tumor immunotherapy due to their limited expression in normal
tissues (Simpson et al., 2005). MAGE-b, in particular, is highly
expressed in over 90% of breast tumors (De Backer et al., 1995;
Park et al., 2002). For this reason, Kim et al constructed sev-
eral Lm-based vaccines containing regions of MAGE-b fused to
dtLLO (Kim et al., 2008). In a mixed prophylactic and therapeu-
tic vaccination regimen, mice were administered twice with one
of four Lm-Mage-b vaccines prior to tumor challenge with 4T1
mammary carcinoma cells and then subsequent administration
of a third vaccination. Surprisingly, vaccination with one vac-
cine, Lm-LLO-Mage-b/2nd resulted in significantly reduced 4T1
lungmetastases as compared to control vaccination but no impact
on primary tumor growth. Further examination discovered that
elevated expression of IL-6 by the primary tumor was the likely
FIGURE 3 | Lm-based vaccine clinical trials pipeline. Numerous Lm-based
vaccines have progressed through the discovery and preclinical phase of
development and are now being administered to oncology patients for a
number of indications. In this figure, we summarize publicly available
information for some of the Lm-based vaccines in clinical testing currently or
planned for clinical testing in the near future.
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culprit for this anti-tumor effect being limited to only metastatic
disease. An additional mechanism of Lm-LLO-Mage-b/2nd anti-
tumor efficacy was subsequently discovered involving direct
killing of infected tumor cells though elevation of cytosolic ROS,
as discussed above (Kim et al., 2009).
p53
The tumor suppressor p53 is commonly mutated in tumors and
correlates with decreased survival in breast cancer (Harris and
Hollstein, 1993). However, mutations in p53 can also result in
tumor cell-specific overexpression and render them susceptible to
killing by p53-specific CTLs (Zambetti and Levine, 1993; Nikitina
et al., 2001). Therefore, Ishizaki et al. constructed an Lm-based
vaccine targeting human p53, LmddA-LLO-p53, and assessed its
anti-tumor efficacy against 4T1 tumor cells stably expressing
mutant human p53 (4T1p53) in tolerant human p53 knock-
in (Hupki) mice (Ishizaki et al., 2010). While LmddA-LLO-p53
administration alone provided some prophylactic and therapeu-
tic efficacy against 4T1p53 tumors, p53-specific immunity and
prophylactic efficacy were dramatically improved when given
with a modified vaccinia Ankara vaccine expressing human p53
(MVA-p53) in a heterologous prime/boost approach. Therapeutic
efficacy and survival were also further improved when adjuvants
(Poly I:C and CpG-ODN) were incorporated into the heterolo-
gous prime/boost regimen. Therefore, this study provides addi-
tional evidence that maximal anti-tumor efficacy of Lm-based
vaccines may sometimes be achieved only when given in a com-
binatorial approach (Hannan et al., 2012; Mkrtichyan et al.,
2013).
TUMOR-ASSOCIATED VASCULATURE
Lm-based vaccines targeting TAAs have demonstrated promise in
numerous preclinical studies, however, the appearance of tumor
immunoediting and tumor immune escape, likely due in part
to the genetic instability of tumor cells (Cahill et al., 1998), has
presented a challenge (Singh and Paterson, 2007a). Therefore,
focus turned to targeting TAAs expressed by cell types believed
to have greater genetic stability such as the tumor-associated vas-
cular endothelial cells (Seavey and Paterson, 2009; Wood et al.,
2011). Tumor-associated vascular endothelial cells have been suc-
cessfully targeted with passive immunity to treat cancer for several
years but a CTL-mediated approach is still lacking (Kim et al.,
1993). Currently, there are several antigens associated with tumor
vascular endothelial cells with the most well characterized being
the vascular endothelial growth factor (VEGF) and it’s recep-
tor (VEGFR) but others such as Cluster of Differentiation 105
(CD105) are also proving to be promising targets for Lm-based
tumor immunotherapy (Goel and Mercurio, 2013).
High molecular weight melanoma-associated antigen (HMW-MAA)
HMW-MAA was initially discovered as an antigen highly
expressed in melanomas and other malignancies derived from
the neural crest and a previous target of tumor immunother-
apy (Campoli et al., 2004; Chang et al., 2004). In an effort
to determine if an Lm-based immunotherapy targeting HMW-
MAA would be effective against mouse models of melanoma,
initial studies were performed against the B16F10 melanoma
cell line stably expressing HMW-MAA along with an Lm vac-
cine expressing a region of HMW-MAA, Lm-LLO-HMWMAA-C
(Maciag et al., 2008). While Lm-LLO-HMWMAA-C success-
fully reduced growth of a melanoma tumor expressing HMW-
MAA, unexpected results were found in experiments targeting
tumor cells that did not express HMW-MAA. Most strikingly,
in two breast cancer models, Lm-LLO-HMWMAA-C, reduced
breast tumor burden and increased time to progression in a
Her2/neu transgenic autochthonous breast tumor model. Further
examination of this unexpected efficacy determined that expres-
sion of the murine HMW-MAA homolog, AN2, was highly
expressed by pericytes in the tumor vasculature. Pericytes are
mesenchymal cells that express AN2 and are associated with,
and stabilize, vasculature in tumors and the periphery (Schneider
et al., 2001; Baluk et al., 2005; von Tell et al., 2006). After
Lm-LLO-HMWMAA-C vaccination, CD8+ T cells colocalized
with the tumor vasculature and the number of pericytes asso-
ciated with the tumor vasculature was significantly decreased.
Importantly, targeting of pericytes with Lm-LLO-HMWMAA-C
did not impact normal processes associated with neovasculariza-
tion such as wound healing and pregnancy. These observations
may suggest that the specific susceptibility of tumors to pericyte-
targeting therapy is due to the already decreased numbers of
pericytes associated with tumor vasculature (Eberhard et al.,
2000).
VEGFR2/Flk-1
Folkman’s hypothesis that limiting tumor growth could be
achieved by targeting tumor angiogenesis in order to limit
the necessary oxygen and nutrient supply has been realized with
the introduction of bevacuzimab, an antibody against VEGF,
into the clinic (Hurwitz et al., 2004). VEGF receptors are found
on activated vascular endothelium and the murine homolog of
VEGFR2, Flk-1, plays an important role in tumor neovascu-
larization and growth (Kim et al., 1993; Millauer et al., 1993,
1994). However, successful passive immunotherapies such as
bevacuzimab have been met with therapeutic resistance (Ellis
and Hicklin, 2008). In order to determine the efficacy of an
active CTL-mediated immune responses against Flk-1 in tumor
immunotherapy, three separate Lm-based vaccines were con-
structed based on regions of Flk-1 with vaccines targeting extra-
cellular portions of the protein, Lm-Flk-E1 and Lm-Flk-E2, and
intracellular, Lm-Flk-I1 (Seavey et al., 2009a). While each vac-
cine was able to induce specific IFN-γ responses against an MHC
Class I epitope within their respective regions, only two of the vac-
cines, Lm-FlkE1 and Lm-FlkI1, were able to significantly inhibit
Her2/neu+ breast tumor growth, reduce tumor vascularization,
and induce secondary T cell responses against the non-targeted
TAAs, a process known as epitope spreading (Vanderlugt and
Miller, 2002). Interestingly, the anti-tumor efficacy of the Flk-1
targeting vaccines was completely abrogated when examined in
a tolerant Her2/neu transgenic mouse. These results support a
hypothesis that CTL-mediated targeting of antigens on activated
vascular endothelium, such as VEGFR2, can result in anti-tumor
efficacy but epitope spreading to additional TAAs is a requirement
for this efficacy. Support for this theory was found in a follow-up
study demonstrating that autochthonous tumor formation in
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Her2/neu transgenic mouse after Lm-Flk-E1 or Lm-Flk-I1 vac-
cination correlated with the occurrence of mutations in Her2/neu
CTL epitopes within those tumors (Seavey and Paterson, 2009).
Therefore, these studies suggest that therapeutic vaccines target-
ing antigens associated with tumor vasculature alone may not
reach their full potential unless tolerance to TAAs is overcome.
This predicts a possible promising therapeutic strategy of pairing
one Lm-based vaccine targeting tumor vasculature with another
vaccine that is able to break central tolerance to a TAA such as
Lm-cHer2 to maximize therapeutic efficacy.
Endoglin/CD105
While previous studies proved Flk-1 to be an effective target for
impacting tumor vasculature, further studies sought to validate
additional promising tumor vasculature targets in an Lm-based
immunotherapy approach. One subsequent study focused on
a member of the TGF-β receptor complex, endoglin (CD105),
which is highly expressed on the vascular endothelium of tumors
and believed to play a role in tumor neovascularization (Wang
et al., 1993; Perez-Gomez et al., 2005). Previous studies targeting
CD105 with an antibody had already met with some success at
controlling tumor burden in a clinical trial and preclinical models
of cancer (Matsuno et al., 1999; Rosen et al., 2012). To determine
the efficacy of targeting CD105 with an active immunotherapy
approach, two Lm-based vaccines were engineered to secrete dif-
ferent regions of CD105 fused to dtLLO (Wood et al., 2011). Each
vaccine, Lm-LLO-CD105A and Lm-LLO-CD105B, were found
to effectively reduce the growth of Her2/neu+ breast tumors
and delay progression of autochthonous tumor progression in
a Her2/neu transgenic mouse. In addition, vaccination against
CD105 reduced lung metastases in the 4T1 mouse model of
metastatic breast cancer and led to epitope spreading to TAAs as
seen previously with the Flk-1 vaccines. Tumor-associated expres-
sion of CD31 and hemoglobin were also reduced after CD105 vac-
cination demonstrating its promise as a target for CTL-mediated
approaches to limit tumor angiogenesis.
PROSTATE CANCER
Prostate specific antigen (PSA)
The current standard of care for prostate cancer patients involv-
ing radiation and chemotherapy still does not prevent roughly
10–30% of men from having recurrent malignancy (Katz and
McKiernan, 2007). Provenge administration in these patients
results in successful but limited extension of lifespan but it carries
with it the difficulties and high cost associated with autolo-
gous cell-based vaccines (Simoens, 2012). While Provenge targets
PAP, improved efficacy may be found with another promis-
ing target for prostate tumor immunotherapy, prostate-specific
antigen (PSA), a protein widely expressed in prostate adeno-
carcinomas (Cunha et al., 2006). PSA-specific CTL-mediated
approaches developed to therapeutically treat prostate cancer
have shown efficacy in the clinic and provided the rationale
for development of an Lm-based vaccine targeting PSA, Lm-
LLO-PSA (Heiser et al., 2002; Shahabi et al., 2008). Lm-LLO-
PSA vaccination in mice was successful at generating PSA-
specific CTL responses. Administration of Lm-LLO-PSA to mice
bearing T-PSA23 prostate tumors, TRAMP-C murine prostate
adenocarcinoma tumors stably expressing PSA, resulted in erad-
ication of over 80% of tumors along with reduced infiltration of
Tregs into tumors as compared to a control vaccine (Shahabi et al.,
2008). In a comparison of vaccine vectors, Lm-LLO-PSA was also
found to be the most effective at reducing prostate tumor burden
in mice as compared to DNA and vaccinia virus-based vaccines
expressing the same antigen.
A follow-up study with an updated Lm-based vaccine target-
ing PSA, but devoid of antibiotic selection markers, ADXS31-142
(Wallecha et al., 2009) was recently undertaken to determine
whether its anti-tumor efficacy could synergize with the radia-
tion therapy that is commonly administered to prostate cancer
patients (Wallecha et al., 2009; Hannan et al., 2012). After implan-
tation of T-PSA23 tumors, mice were treated with either radiation
followed by three doses of ADXS31-142, radiation alone, or
ADXS31-142 alone. Each treatment resulted in significantly lower
tumor burden as compared to control Lm vaccination but radia-
tion followed by ADXS31-142 vaccination resulted in synergistic
therapeutic anti-tumor efficacy. The mechanism for this synergis-
tic application of radiation and Lm vaccine appeared to be due to
a robust four-fold increase in PSA-specific CTLs in the spleens
of treated mice. These results are in line with previous stud-
ies that documented synergism of irradiation along with tumor
immunotherapy and provide a rational approach for adminis-
tration of Lm-based vaccines in prostate cancer patients (Kantoff
et al., 2010b).
HEPATOCELLULAR CARCINOMA
Multiple peptide fusing genes (MPFG)
In order to mitigate the emergence of tumor immune escape
due to mutation of a single targeted TAA epitope, some have
developed chimeric Lm-based vaccines that incorporate multi-
ple epitopes from regions spanning an entire TAA (Seavey et al.,
2009b; Shahabi et al., 2011). While these studies have met with
success, loss of complete TAA expression due to immune pres-
sure, as previously observed with Her-2/neu, may render even
this approach ineffective (Kmieciak et al., 2007). Therefore, to
further impede the emergence of tumor immune escape, oth-
ers have developed polyvalent therapeutic tumor vaccines that
incorporate epitopes from several TAAs (Tanaka et al., 2002).
Early Lm-based polyvalent vaccines have either contained model
tumor antigens (Bruhn et al., 2005) or were not validated for
in vivo efficacy (Sinnathamby et al., 2009) but a recent study
by Chen et al. documents the validation of an Lm-based poly-
valent vaccine targeting clinically relevant TAAs in a model of
hepatocellular carcinoma (HCC) (Tanaka et al., 2002; Chen et al.,
2012). HCC is a prevalent cause of cancer-related deaths world-
wide, especially in countries such as China where oncogenic
Hepatitis B virus (HBV) infection is endemic (Chen et al., 2012).
In order to develop an effective Lm-based therapeutic vaccine
to treat HCC that overcomes the challenges of immune escape
of previous immunotherapies, the authors constructed a vac-
cine that expressed the entire HBV core protein (HBc) along
with validated HLA-A2 epitopes for additional TAAs including
HBV-X protein, alpha-fetoprotein, and MAGE-A. The result-
ing fusion protein was named multiple peptide fusing genes
(MPFG) and the Lm-based vaccine that expressed this fusion
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protein, Lm-MPFG. Lm-MPGF administration to HLA-A2 trans-
genic mice induced robust IFN-γ and cytolytic responses against
the MPFG antigens. When mice were vaccinated prophylacti-
cally or therapeutically after inoculation with Hepa1-6 tumor
cells expressing MPFG and HLA-A2, Lm-MPFG treatment led to
reduced tumor burden and increased tumor-free survival in com-
parison to a control Lm. The anti-tumor efficacy of Lm-MPFG
correlated with increased infiltrations of MPFG-specific CD8+ T
cells and increased cytolytic potential of CTLs. Additionally, pro-
phylactic and therapeutic administration of Lm-MPFG resulted
in significantly reduced number of Tregs in tumors and reduced
production of anti-inflammatory cytokines such as TGF-β and
IL-10 by the tumor-infiltrating Tregs. This study provides the first
evidence that Lm-based immunotherapies could be effective in
the treatment of HCC but it also demonstrates the validation of
a polyvalent Lm-based vaccine approach that will prove useful in
limiting tumor immune escape.
MELANOMA
TRP-2
Early studies with Lm-based tumor immunotherapies targeting
a mouse model of melanoma, B16F10-NP, demonstrated their
potency against this malignancy. However, these studies were tar-
geting the model tumor antigen influenza nucleoprotein, NP,
and not a melanoma-specific TAA that is clinically relevant (Pan
et al., 1999). One melanoma-specific TAA that previously was
found to be immunogenic and a validated target for tumor
immunotherapy is Tyrosinase-related protein-2 (TRP-2) (Bloom
et al., 1997). TRP-2 is a melanogenic enzyme expressed specif-
ically by melanocytes and melanoma cells (Wang et al., 1996).
To determine the therapeutic efficacy of targeting TRP-2 with
Lm-based immunotherapy, Bruhn et al. constructed several Lm-
based vaccines expressing either TRP-2 alone or fused to anMHC
class I H-2Db-restricted epitope from LCMV NP (a.a. 396–404)
(Bruhn et al., 2005). While either vaccine was capable of induc-
ing TRP-2-specific CD8+ T cell responses, studies determining
anti-tumor efficacy were subsequently carried out with only
the Lm-TRP2-NP construct. After two prophylactic vaccinations
with Lm-TRP2-NP and subsequent challenge with B16 tumors,
mice receiving the TRP-2 vaccine had significantly reduced tumor
burden as compared to mice that received the control Lm, Lm-
NP, or empty Lm vector. The Lm-TRP2-NP vaccine was also
found to be therapeutically effective against B16-MO5 metastatic
lesions, a variant of the B16 tumor cell line stably expressing
chicken ovalbumin (Falo et al., 1995). A follow-up study also
demonstrated the ability of Lm-TRP2-NP to provide protective
immunity in a B16 brain metastasis model (Prins et al., 2006). To
further improve the anti-tumor efficacy of Lm-TRP2-NP, it was
administered in combination with the TLR7 agonist, imiquimod
(Craft et al., 2005). Imiquimod was previously found to be a
strong adjuvant and lead to reduced tumor growth alone. When
administered along with Lm-TRP2-NP, it enhanced the prophy-
lactic anti-tumor efficacy of Lm-TRP2-NP in both primary and
metastatic B16 tumor challenge models. The findings from these
studies validate Lm-based immunotherapies as effective induc-
ers of anti-tumor immune responses to sites of metastatic spread
that are normally considered immune-privileged, a finding later
confirmed in a mouse model for breast cancer by Shahabi et al.
(2011).
CLINICAL TRIALS WITH Lm-BASED VACCINES
FIRST SAFETY TRIAL WITH EMPTY Lm VACCINE STRAIN
The first human safety trial for an attenuated Lm-based empty
vaccine vector was reported in 2002 by Angelakopoulos et al.
(2002). For this study, the authors sought to administer an Lm
strain that was highly attenuated with little risk of reversion to
a more virulent state. To accomplish this, the Lm strain used for
this study contained genetic deletions of two common virulence
factors produced by Lm, actA, and plcB. Additional measures to
confirm the safety of this Lm vaccine strain confirmed the inabil-
ity of this strain to revert to a more virulent phenotype after 30
serial passages on agar. Twenty healthy volunteers ingested, in
25mL of saline, the Lm vaccine strain in escalating doses from 106
CFUs up to 109 CFUs.While 75% of the volunteers had detectable
shedding of the Lm vaccine strain in their stool for up to four days
after administration, no serious adverse events occurred with only
transient increases in liver enzymes observed in two volunteers.
Antibody responses to the Lm vaccine strain were minimal with
no detectable Lm-specific IgA, but all four volunteers in the group
receiving the highest dose (109 CFU) had detectable Lm-specific
IFN-γ responses suggesting the vaccine was successful at induc-
ing the formation of Lm-specific T cell responses. The results
from this first human trial with an Lm vaccine strain provided
confidence in the ability of attenuated Lm strains to safely and
effectively induce antigen-specific T cell responses in humans.
Lm-LLO-E7 (ADXS-HPV) FOR CERVICAL CANCER
The preclinical success of Lm-LLO-E7 resulted in its introduc-
tion into the clinic for a Phase I trial in patients with invasive
carcinoma of the cervix (ICC), a prevalent HPV-induced cancer
in many developing countries (Cutts et al., 2007; Maciag et al.,
2009). As a Phase I trial, the safety and tolerability of Lm-LLO-
E7 in humans were of primary interest but additional parameters
such as objective response as determined by Response Evaluation
Criteria in Solid Tumors (RECIST) criteria and overall survival
were also measured (Eisenhauer et al., 2009). Fifteen patients
with ICC, most having failed previous therapeutic regimens, were
placed into three treatment groups with each scheduled to receive
two vaccinations three weeks apart with 1× 109, 3.3× 109, or
1× 1010 CFUs of Lm-LLO-E7. All patients reported adverse
events after receiving Lm-LLO-E7 with the most common being
pyrexia in all patients following by vomiting, headache, and ane-
mia. All adverse events were transient and grade 3 or lower with
the most severe related to Lm-LLO-E7 infection. Dose-limiting
toxicities were observed, however, only in the group receiving the
highest dose of 1× 1010 CFUs. In addition, a delayed increase
in liver enzymes was observed in some patients one week after
administration. This increase was likely not due to a current infec-
tion as all patients received antibiotics three days after admin-
istration of Lm-LLO-E7. While two deaths occurred, unrelated
to Lm-LLO-E7 administration, over half of the remaining sub-
jects had objective stable disease by RECIST criteria with one
patient having a partial response. Overall survival for all evaluable
patients was 347 days at the end of the study with two surviving
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subjects. This compares favorably to the current median overall
survival of ICC patients receiving standard of care chemotherapy
ranging from 6.5 to 9.4 months (Monk et al., 2009). Therefore,
the results from this study were very promising in terms of toler-
ability and overall survival in a patient population with very few
effective therapeutic options. While the adverse events observed
in this study were of a higher grade andmore prevalent than those
observed in the previous Angelakopoulos et al. study (2002), the
intravenous administration in this study as compared to oral
administration likely accounts for the increased virulence of the
infection.
The promising results from the Phase I trial with Lm-LLO-
E7 (Maciag et al., 2009) resulted in its further development to
a Phase II clinical trial in India initiated in 2010 and ended
with its last patient visit in the fall of 2013 (Petit and Basu,
2013). The study enrolled 110 patients with ICC and placed them
into two treatment groups, one receiving three doses of 1× 109
CFU of Lm-LLO-E7 and the second receiving 4 doses of 1× 109
CFU of Lm-LLO-E7 along with cisplatin, an alkylating platinum-
based chemotherapy (Siddik, 2003), The final 12-month survival
among all patients was 36% and 18-month survival is currently
at 28% at study end. In addition, five complete responses and
six partial responses were observed. These results compare favor-
ably with the previous Gynecologic Oncology Group (GOG)
trials featuring a combined paclitaxel and cisplatin treatment reg-
imen with a 12-month survival of 32% and 18-month survival
at 22%. There were no observed differences in responses or sur-
vival between the two treatment arms. Although Lm-LLO-E7
was constructed using HPV16 E7, responses were observed in
patients with tumors transformed by several different high risk
HPV strains including HPV16, 18, 31, 33, and 45.
Mild to moderate adverse events were observed in less than
half of patients with only 2% experiencing grade 3 or greater
adverse events. This also compares favorably to the current
standard-of-care chemotherapy with grade 3 or greater adverse
event rates nearing 100% (Monk et al., 2009). The adverse events
related to Lm-LLO-E7 appeared to correlate with the magnitude
of innate immunity activation after administration suggesting
serum cytokines could be used in the future to monitor patient
responses. Overall, the combined results of each of the Lm-LLO-
E7 clinical trials demonstrate an effective new therapeutic option
for patients battling advanced cervical cancer but with reduced
side-effects compared to current treatments (Monk et al., 2009).
The promising results from the completed Lm-LLO-E7 clinical
trails have resulted in its continued development as a therapeutic
for advanced cervical cancer, with another Phase II study cur-
rently being conducted by the Gynecologic Group in the US, but
also other HPV-associated malignancies. These studies were per-
formed by Advaxis Inc. who have renamed the Lm-LLO-E7 vector,
ADXS-HPV (http://www.advaxis.com/clinical-pipeline).
ANZ100 AND CRS207
A pair of studies reported by Le et al. (2012) described the admin-
istration two novel live attenuated double-deletion (LADD) Lm
vaccine strains (Le et al., 2012). The first study, much like
Angelakopoulos et al. (2002), involved administration of an
empty Lm vaccine strain, ANZ-100, that contains deletions for
two Lm virulence factors, actA, and inlB. The ANZ-100 study
consisted of 9 patients (6 with colorectal cancer, 2 with pancre-
atic ductal carcinoma, and 1 with melanoma) that each received a
single intravenous infusion of either 1x106, 3x107, or 3x108 CFUs
of the attenuated Lm. ANZ-100 was well tolerated by the patients
at all doses with transient adverse events such as lymphopenia,
hyperglycemia, hypophosphatemia, and fever in most patients
but no observed dose-limiting toxicities. Within 2 days after dos-
ing, a sharp drop in circulating NK cells and increased NK cell
expression of CD38 suggested that ANZ-100 was stimulating NK
cell activation and extravasation into infected tissues. ANZ-100-
induced NK cell activation corresponded with a sharp transient
rise in serum proinflammatory cytokines and chemokines in
a dose-dependent manner. While patient follow-ups were not
reported, this study demonstrated that LADD are safe for use in
cancer patients and can induce proinflammatory responses that
are critical for effective anti-tumor immunity.
Further work continued with a similar LADD construct but
one that expressed the TAA mesothelin as part of a fusion protein
with ActA, termed CRS-207. Mesothelin is a glycoprotein nor-
mally expressed in mesothelial cells but highly overexpressed in a
number of different tumor types making it a promising target for
tumor immunotherapy (Thomas and Hassan, 2012). The CRS-
207 study was comprised of 17 patients, each with a type of cancer
associated with elevated expression of mesothelin including ovar-
ian, pancreatic, mesothelioma, and non-small cell lung cancer.
Each patient received four infusions of CRS-207 three weeks apart
and separated into four groups based on the dosage of CRS-207
received, either 108, 3× 108, 109, or 1010 CFUs. Treatment-
related toxicities were comparable to the ANZ-100 study with one
observed dose-limiting toxicity in a patient receiving 1010 CFUs.
The maximum-tolerated dose was therefore determined to be 109
CFU of CRS-207. As previously observed with ANZ-100, CRS-
207 also induced proinflammatory cytokines and chemokines but
the dose-dependence was not as clear with the highest dose, 1010
CFUs, inducing the least amount of proinflammatory cytokines
such as IFN-γ and IL-12. As only one patient received the high-
est dose, the lack of dose-dependence could be due to lack of
statistical power. Mesothelin and LLO-specific T cell responses
were observed in patients from all groups receiving up to 109
CFUs of CRS-207. In terms of efficacy, over 37% of patients sur-
vived for greater than 15 months with responses and survival
independent of the dosage administered and the type of cancer
treated. Interestingly, the best predictor of long-term survival in
this population after CRS-207 administration was the presence of
LLO-specific T cell responses in the periphery but not those to
mesothelin. The authors suggest this correlation may be predic-
tive of the immune competency of the patient. The results of the
CRS-207 Phase I study were promising in terms of overall sur-
vival for a set of patients with further work needed to elucidate
the mechanisms governing its efficacy.
Lm-BASED IMMUNOTHERAPIES GOING FORWARD
The current state of Lm-based immunotherapies provides a great
deal of optimism for their future in the clinic as safer and more
effective therapeutic options than current treatment regimens as
evidenced by the recent clinical findings with ADXS-HPV and a
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robust clinical pipeline summarized in Figure 3 (Maciag et al.,
2009; Petit and Basu, 2013). However, several preclinical stud-
ies covered within this review suggest advancements that will
likely influence construction strategies going forward and lead to
improved Lm-based immunotherapies. As the studies with Lm-
Her2 constructs demonstrated, one major challenge for tumor
immunotherapies targeting a single TAA is the eventual selection
for mutated TAAs in the targeted tumors and immune escape
(Singh and Paterson, 2007a). The study by Chen et al, how-
ever, suggests that incorporating multiple epitopes from several
antigens into a polyvalent vaccine could be an effective strat-
egy going forward for Lm-based immunotherapies to mitigate
immune escape (Chen et al., 2012). In addition to the develop-
ment of polyvalent Lm-based vaccines, it is expected that new
constructs may leverage the tumor tropism of their attenuated Lm
vaccines (Kim et al., 2009; Quispe-Tintaya et al., 2013). As elegant
studies from the Gravekamp laboratory have elucidated, the pri-
mary and metastatic tumor tropism and killing by Listeria could
possibly be harnessed to effectively treat stubborn malignan-
cies such as pancreatic ductal carcinoma (Quispe-Tintaya et al.,
2013). This tumor tropism suggests a possible synergistic strat-
egy of Lm-based vaccines going forward to deliver therapeutic
proteins or expression plasmids to the tumor microenvironment
as previously demonstrated (Stritzker et al., 2008) in addition to
TAAs for induction of a tumor-specific CTL response (Souders
et al., 2006; Stritzker et al., 2008). Finally, the synergism of
Lm-based immunotherapies in combination with radiation, adju-
vants, and therapeutic antibodies suggests a versatility that we
are only just uncovering (Ishizaki et al., 2010; Hannan et al.,
2012; Mkrtichyan et al., 2013). Each of these promising devel-
opments along with growing list of ongoing and upcoming
clinical trials of Lm-based immunotherapies for cancer demon-
strate that we are just now realizing the goals of William Coley a
century ago.
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